Medtronic has reported successful findings from two real-world analyses conducted to assess its AdaptivCRT algorithm in a total of 408 patients suffering from heart failure.
Data showed that the algorithm led to decrease in atrial fibrillation (AF) episodes and higher patient activity levels.
The AdaptivCRT algorithm has been designed to adjust the pacing mechanism of the implanted device based on individual patient’s minute-to-minute evaluations of heart rhythm.
Both the studies were conducted at 26 centres in Italy and included Medtronic cardiac resynchronisation therapy (CRT) device.
During the first analysis, a significant reduction in the incidence of AF episodes was observed for all measured durations in 210 subjects on AdaptivCRT compared to 198 participants with conventional CRT.
Furthermore, AdaptivCRT is reported to have significantly and independently demonstrated a higher daily activity level for patients with the AdaptivCRT ON in the second analysis.
Medtronic Cardiac Resynchronization Therapy business vice-president and general manager Kweli Thompson said: “The AdaptivCRT feature continues to perform consistently in a variety of settings, the rigour of a randomised, controlled trial, as well as in real-world settings, and is associated with a significantly reduced risk of AF.
“Our broad portfolio of cardiac devices helps physicians detect, reduce, respond to and treat AF.”
Results from a prior randomised clinical trial revealed that AdaptivCRT increases the rate of CRT response, minimises unnecessary pacing for the right ventricle and improves outcomes for patients with normal AV conduction.
Further analyses showed that the algorithm decreases risk for AF and 30-day heart failure readmission.